Back to results
US 2026/0028328 A1Published application
HETEROARYL DERIVATIVES AS DDRs INHIBITORS
AssigneeChiesi Farmaceutici S.p.A.
InventorsRoberta MAZZUCATO, Nicolò IOTTI, Laura CARZANIGA, Andrea RIZZI, Eleonora GHIDINI, Benjamin Paul WHITTAKER, Annarita CIANCIUSI, Robert Stuart Laurie CHAPMAN, Zuzana HAMASOVA
Life of this patent
Estimating the term…
Abstract
The present invention relates to compounds of formula (I) inhibiting Discoidin Domain Receptors (DDR inhibitors), methods of preparing such compounds, intermediate compounds useful in such preparations, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful for instance in the treatment of many disorders associated with DDR mechanisms.
Claims15
1:
- A compound of formula (I)
- wherein
- A is a ring selected from the group consisting of:
- and phenyl, wherein indicates a direct bond to NH;
- W1 and W2 are substituents of ring A selected from the group consisting of hydrogen, halogen, (C1-C4)alkyl, (C1-C4)haloalkyl, (C1-C4)alkoxy, (C1-C4)haloalkoxy, R1R2N—(C1-C4)alkyl and (C3-C6)cycloalkyl;
- Z is selected from the group consisting of (C1-C4)alkyl, (C1-C4)haloalkyl, (C1-C4)alkoxy, (C1-C4)haloalkoxy, (C1-C4)hydroxyalkyl and (C3-C6)cycloalkyl;
- L is selected from the group consisting of
- wherein indicates a direct bond to the phenyl ring and
- indicates a direct bond to B;
- B is mono- or bi-cyclic heteroaryl ring;
- Y1 and Y2 are substituents of ring B independently selected from the group consisting of hydrogen, (C1-C4)alkyl, (C1-C4)haloalkyl, (C1-C4)alkoxy, (C1-C4)alkoxy-(C1-C4)alkoxy, hydroxy-(C1-C4)alkoxy, hydroxy-(C1-C4)alkyl, (C1-C4)alkyl-heterocycloalkyl-(C0-C4)alkoxy, (C1-C4)haloalkoxy, halogen, cyano, cyano-(C1-C4)alkyl, cyano-(C1-C4)alkyl-heterocycloalkyl, CONR1R2, NHCOR1, NR1R2, R1R2N—(C1-C4)alkyl, heterocycloalkyl, (C1-C4)alkyl-heterocycloalkyl, heterocycloalkyl-(C1-C4)alkyl, (C1-C4)alkyl-heterocycloalkyl-carbonyl, (C0-C4)alkyl-heterocycloalkyl-carbonyl, (C1-C4)alkyl-phenyl and monocyclic (C1-C4)alkyl-heteroaryl;
- R1 and R2 are independently selected from the group consisting of hydrogen, (C1-C4)alkyl, (C1-C4)hydroxyalkyl, (C1-C4)alkoxy(C1-C4)alkyl, (C1-C4)alkylamino-(C1-C4)alkyl, di-(C1-C4)alkylamino-(C1-C4)alkyl, optionally substituted (C3-C6)cycloalkyl, optionally substituted heterocycloalkyl and optionally substituted heterocycloalkyl-(C1-C4)alkoxy, wherein optional substituents are one or more and are selected from (C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)haloalkyl and (C1-C4)haloalkoxy;
- and
- R3 is selected from the group consisting of hydrogen and (C1-C4)alkyl;
- or a stereoisomer, tautomer, solvate or pharmaceutically acceptable salt thereof.
12 more elements
2:
- The compound, or stereoisomer, tautomer, solvate or pharmaceutically acceptable salt thereof, according to claim 1 wherein the compound has a formula (Ic)
- wherein L1 is selected from the group consisting of O, NR3, CHR3, S and SO2, or is absent.
3:
- The compound, or stereoisomer, tautomer, solvate or pharmaceutically acceptable salt thereof, according to claim 1, wherein
- B is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, pyrazolo[1,5-a]pyrazinyl, 1H-pyrazolo[3,4-b]pyridinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-b]pyridazinyl, imidazo[1,2-a]pyrazinyl, imidazo[1,2-a]pyridinyl, thieno[3,2-d]pyrimidinyl, 1H-pyrrolo[2,3-b]pyridinyl and pyrazolyl.
4:
- The compound, or stereoisomer, tautomer, solvate or pharmaceutically acceptable salt thereof, according to claim 1, wherein
- A is a ring selected from the group consisting of:
- and phenyl.
5:
- The compound, or stereoisomer, tautomer, solvate or pharmaceutically acceptable salt thereof, according to claim 1, wherein
- W1 and W2 are selected from the group consisting of H, F, CH3, OCH3, OCF3, CF3, C(CH3)3, CH2CH3, C(CH3)2CF3, OCF2H, CHF2, CH2CF3, CH2N(CH3)2 and cyclopropyl;
- Z is selected from the group consisting of CH3, CF2H, OCH3, CH2OH and cyclopropyl;
- L is selected from the group consisting of
- B is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, pyrazolo[1,5-a]pyrazinyl, 1H-pyrazolo[3,4-b]pyridinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-b]pyridazinyl, imidazo[1,2-a]pyrazinyl, imidazo[1,2-a]pyridinyl, thieno[3,2-d]pyrimidinyl, 1H-pyrrolo[2,3-b]pyridinyl and pyrazolyl;
- Y1 is selected from the group consisting of hydrogen, (C1-C4)haloalkyl, (C1-C4)alkoxy, cyano, CONR1R2, NHCOR1, NR1R2, (C1-C4)alkyl-heterocycloalkyl-carbonyl and monocyclic (C1-C4)alkyl-heteroaryl;
- and Y2 is hydrogen;
- R1 and R2 are independently selected from the group consisting of CH2CH2N(CH3)2, CH2CH2OCH3, CH3, CH2CH2OH, oxetan-3-yl and 3-hydroxycyclobutyl;
- and
- R3 is hydrogen or methyl.
7 more elements
6:
- The compound, or stereoisomer, tautomer, solvate or pharmaceutically acceptable salt thereof, according to claim 1, wherein the compound of formula (I) is selected from the group consisting of:
- 4-methyl-3-((1-(pyrimidin-5-yl)azetidin-3-yl)oxy)-N-(5-(trifluoromethyl) pyridin-3-yl)benzamide (Example 135);
- 4-methyl-3-((1-(pyrazolo[1,5-a]pyrazin-3-yl)azetidin-3-yl)oxy)-N-(5-(trifluoromethyl)pyridin-3-yl)benzamide (Example 136);
- 3-((1-(imidazo[1,2-a]pyridin-3-yl)azetidin-3-yl)oxy)-4-methyl-N-(5-(trifluoromethyl)pyridin-3-yl)benzamide (Example 137);
- 3-((1-(5-acetamidopyrazolo[1,5-a]pyrimidin-3-yl)azetidin-3-yl)oxy)-4-methyl-N-(5-(trifluoromethyl)pyridin-3-yl)benzamide (Example 138);
- 5-(3-(2-methyl-5-((5-(trifluoromethyl)pyridin-3-yl)carbamoyl)phenoxy)azetidin-1-yl)nicotinamide (Example 139);
- 4-methyl-3-((1-(5-(methylamino)pyrazolo[1,5-a]pyrimidin-3-yl)azetidin-3-yl)oxy)-N-(5-(trifluoromethyl)pyridin-3-yl)benzamide (Example 141);
- 4-methyl-3-((1-(pyrazolo[1,5-a]pyrimidin-3-yl)azetidin-3-yl)oxy)-N-(5-(trifluoromethyl)pyridin-3-yl)benzamide (Example 142);
- 4-methyl-3-((1-(5-(1-methyl-1H-pyrazol-4-yl)pyridin-3-yl)azetidin-3-yl)oxy)-N-(5-(trifluoromethyl)pyridin-3-yl)benzamide (Example 143);
- 3-((1-(5-acetamidopyridin-3-yl)azetidin-3-yl)oxy)-4-methyl-N-(5-(trifluoromethyl)pyridin-3-yl)benzamide (Example 145);
- 3-((1-(imidazo[1,2-a]pyrazin-3-yl)azetidin-3-yl)oxy)-4-methyl-N-(5-(trifluoromethyl)pyridin-3-yl)benzamide (Example 146);
- N-(5-ethylisoxazol-3-yl)-4-methyl-3-((1-(pyrazolo[1,5-a]pyrazin-3-yl)azetidin-3-yl)oxy)benzamide (Example 152);
- N-(2-methoxy-5-(trifluoromethyl)phenyl)-4-methyl-3-((1-(pyrazolo[1,5-a]pyrazin-3-yl)azetidin-3-yl)oxy)benzamide (Example 153);
- N-(5-(tert-butyl)-1-methyl-1H-pyrazol-3-yl)-4-methyl-3-((1-(pyrazolo[1,5-a]pyrazin-3-yl)azetidin-3-yl)oxy)benzamide (Example 154);
- N-(5-(tert-butyl)isoxazol-3-yl)-4-methyl-3-((1-(pyrazolo[1,5-a]pyrazin-3-yl)azetidin-3-yl)oxy)benzamide (Example 155);
- 4-methyl-3-((1-(pyrazolo[1,5-a]pyrazin-3-yl)azetidin-3-yl)oxy)-N-(5-(trifluoromethoxy)pyridin-3-yl)benzamide (Example 157);
- N-(2-methoxy-5-(trifluoromethoxy)phenyl)-4-methyl-3-((1-(pyrazolo[1,5-a]pyrazin-3-yl)azetidin-3-yl)oxy)benzamide (Example 158);
- 4-methyl-N-(2-methyl-5-(trifluoromethoxy)phenyl)-3-((1-(pyrazolo[1,5-a]pyrazin-3-yl)azetidin-3-yl)oxy)benzamide (Example 159);
- N-(2-chloro-5-(trifluoromethyl)phenyl)-4-methyl-3-((1-(pyrazolo[1,5-a]pyrazin-3-yl)azetidin-3-yl)oxy)benzamide (Example 160);
- 4-methyl-3-((1-(pyrazolo[1,5-a]pyrazin-3-yl)azetidin-3-yl)oxy)-N-(3-(trifluoromethoxy)phenyl)benzamide (Example 161);
- N-(3-fluoro-5-(trifluoromethyl)phenyl)-4-methyl-3-((1-(pyrazolo[1,5-a]pyrazin-3-yl)azetidin-3-yl)oxy)benzamide (Example 162);
- N-(3-(tert-butyl)-1-methyl-1H-pyrazol-5-yl)-4-methyl-3-((1-(pyrazolo[1,5-a]pyrazin-3-yl)azetidin-3-yl)oxy)benzamide (Example 163);
- 4-methyl-3-((1-(pyrazolo[1,5-a]pyrazin-3-yl)azetidin-3-yl)oxy)-N-(3-(2,2,2-trifluoroethyl)phenyl)benzamide (Example 164);
- 3-((1-(5-(difluoromethyl)pyridin-3-yl)azetidin-3-yl)oxy)-4-methyl-N-(5-(trifluoromethyl)pyridin-3-yl)benzamide (Example 165);
- 4-methyl-3-((1-(5-(4-methylpiperazin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)azetidin-3-yl)oxy)-N-(5-(trifluoromethyl)pyridin-3-yl)benzamide (Example 166);
- 4-methyl-3-((1-(5-methylpyrazolo[1,5-a]pyrimidin-3-yl)azetidin-3-yl)oxy)-N-(5-(trifluoromethyl)pyridin-3-yl)benzamide (Example 167);
- 4-methyl-3-((1-(pyrazolo[1,5-a]pyridin-3-yl)azetidin-3-yl)oxy)-N-(5-(trifluoromethyl)pyridin-3-yl)benzamide (Example 168);
- 4-methyl-3-((1-(1-methyl-1H-pyrazolo[3,4-c]pyridin-4-yl)azetidin-3-yl)oxy)-N-(5-(trifluoromethyl)pyridin-3-yl)benzamide (Example 169);
- 4-methyl-3-((1-(5-morpholinopyrazolo[1,5-a]pyrimidin-3-yl)azetidin-3-yl)oxy)-N-(5-(trifluoromethyl)pyridin-3-yl)benzamide (Example 170);
- 3-((1-(5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)azetidin-3-yl)oxy)-4-methyl-N-(5-(trifluoromethyl)pyridin-3-yl)benzamide (Example 173);
- 3-((1-(4-cyanopyridin-3-yl)azetidin-3-yl)oxy)-4-methyl-N-(5-(trifluoromethyl)pyridin-3-yl)benzamide (Example 174);
- 3-((1-(5-(4-(hydroxymethyl)piperidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)azetidin-3-yl)oxy)-4-methyl-N-(5-(trifluoromethyl)pyridin-3-yl)benzamide (Example 180);
- 4-(difluoromethoxy)-3-((1-(pyrazolo[1,5-a]pyrazin-3-yl)azetidin-3-yl)oxy)-N-(5-(trifluoromethyl)pyridin-3-yl)benzamide (Example 182);
- 4-methoxy-3-((1-(pyrazolo[1,5-a]pyrazin-3-yl)azetidin-3-yl)amino)-N-(5-(trifluoromethyl)pyridin-3-yl)benzamide (Example 183);
- 4-methyl-3-((1-(pyrimidin-5-yl)azetidin-3-yl)amino)-N-(5-(trifluoromethyl) pyridin-3-yl)benzamide (Example 134);
- 4-methyl-3-((1-(pyrazolo[1,5-a]pyrazin-3-yl)azetidin-3-yl)amino)-N-(5-(trifluoromethyl)pyridin-3-yl)benzamide (Example 140);
- 4-methyl-3-((1-(5-(1-methyl-1H-pyrazol-4-yl)pyridin-3-yl)azetidin-3-yl)amino)-N-(5-(trifluoromethyl)pyridin-3-yl)benzamide (Example 144);
- 3-((1-(imidazo[1,2-a]pyrazin-3-yl)azetidin-3-yl)amino)-4-methyl-N-(5-(trifluoromethyl)pyridin-3-yl)benzamide (Example 147);
- 4-methyl-3-((1-(pyrazolo[1,5-a]pyrimidin-3-yl)azetidin-3-yl)amino)-N-(5-(trifluoromethyl)pyridin-3-yl)benzamide (Example 148);
- N-(3-(tert-butyl)isoxazol-5-yl)-4-methyl-3-((1-(pyrazolo[1,5-a]pyrazin-3-yl) azetidin-3-yl)amino)benzamide (Example 149);
- N-(5-(tert-butyl)isoxazol-3-yl)-4-methyl-3-((1-(pyrazolo[1,5-a]pyrazin-3-yl) azetidin-3-yl)amino)benzamide (Example 150);
- N-(5-(tert-butyl)-1-methyl-1H-pyrazol-3-yl)-4-methyl-3-((1-(pyrazolo[1,5-a]pyrazin-3-yl)azetidin-3-yl)amino)benzamide (Example 156);
- 4-(difluoromethoxy)-3-((1-(pyrazolo[1,5-a]pyrazin-3-yl)azetidin-3-yl)amino)-N-(5-(trifluoromethyl)pyridin-3-yl)benzamide (Example 181);
- 4-methyl-3-(methyl(1-(pyrazolo[1,5-a]pyrazin-3-yl)azetidin-3-yl)amino)-N-(5-(trifluoromethyl)pyridin-3-yl)benzamide (Example 151);
- 4-methyl-3-((1-(pyrazolo[1,5-a]pyrazin-3-yl)azetidin-3-yl)methyl)-N-(5-(trifluoromethyl)pyridin-3-yl)benzamide (Example 171);
- 4-methyl-3-(1-(1-(pyrazolo[1,5-a]pyrazin-3-yl)azetidin-3-yl)ethyl)-N-(5-(trifluoromethyl)pyridin-3-yl)benzamide (Example 172);
- 4-methyl-3-(1-(1-(pyrazolo[1,5-a]pyrazin-3-yl)azetidin-3-yl)ethyl)-N-(5-(trifluoromethyl)pyridin-3-yl)benzamide, 1st eluted enantiomer (Example 175);
- 4-methyl-3-(1-(1-(pyrazolo[1,5-a]pyrazin-3-yl)azetidin-3-yl)ethyl)-N-(5-(trifluoromethyl)pyridin-3-yl)benzamide, 2nd eluted enantiomer (Example 176);
- 4-methyl-3-((1-(pyrimidin-5-yl)azetidin-3-yl)thio)-N-(5-(trifluoromethyl)pyridin-3-yl)benzamide (Example 177);
- 4-methyl-3-((1-(pyrazolo[1,5-a]pyrazin-3-yl)azetidin-3-yl)thio)-N-(5-(trifluoromethyl)pyridin-3-yl)benzamide (Example 178);
- 4-methyl-3-((1-(pyrazolo[1,5-a]pyrazin-3-yl)azetidin-3-yl)sulfonyl)-N-(5-(trifluoromethyl)pyridin-3-yl)benzamide (Example 179);
- and
- 4-methyl-3-(1-(pyrazolo[1,5-a]pyrazin-3-yl)azetidin-3-yl)-N-(5-(trifluoromethyl)pyridin-3-yl)benzamide (Example 184).
50 more elements
7:
- A pharmaceutical composition comprising the compound, or stereoisomer, tautomer, solvate or pharmaceutically acceptable salt thereof, according to claim 1, in admixture with at least one pharmaceutically acceptable carrier and/or excipient.
8:
- The pharmaceutical composition according to claim 7, which is formulated for administration by inhalation.
(canceled)
10:
- A method of treating a disease, disorder or condition associated with dysregulation of DDR, comprising administering the pharmaceutical composition of claim 7 to a subject in need thereof.
11:
- A method of treating fibrosis and/or a disease, disorder or condition that involves fibrosis, comprising administering the pharmaceutical composition of claim 7 to a subject in need thereof.
12:
- The method according to claim 11, wherein the fibrosis is at least one selected from the group consisting of pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF), hepatic fibrosis, renal fibrosis, ocular fibrosis, cardiac fibrosis, arterial fibrosis and systemic sclerosis.
13:
- The method according to claim 12, wherein the fibrosis comprises idiopathic pulmonary fibrosis (IPF).
14:
- An intermediate compound selected from the group consisting of a compound of formula (XXXIII)
- an intermediate compound of formula (XXXIX)
- and an intermediate compound of formula (XL)
- wherein
- R is (C1-C4)alkyl,
- A is a ring selected from the group consisting of:
- and phenyl, wherein indicates a direct bond to NH;
- W1 and W2 are substituents of ring A selected from the group consisting of hydrogen, halogen, (C1-C4)alkyl, (C1-C4)haloalkyl, (C1-C4)alkoxy, (C1-C4)haloalkoxy, R1R2N—(C1-C4)alkyl and (C3-C6)cycloalkyl;
- Z is selected from the group consisting of (C1-C4)alkyl, (C1-C4)haloalkyl, (C1-C4)alkoxy, (C1-C4)haloalkoxy, (C1-C4)hydroxyalkyl and (C3-C6)cycloalkyl;
- L1 is selected from the group consisting of O, NR3, CHR3, S and SO2, or is absent;
- B is mono- or bi-cyclic heteroaryl ring;
- Y1 and Y2 are substituents of ring B independently selected from the group consisting of hydrogen, (C1-C4)alkyl, (C1-C4)haloalkyl, (C1-C4)alkoxy, (C1-C4)alkoxy-(C1-C4)alkoxy, hydroxy-(C1-C4)alkoxy, hydroxy-(C1-C4)alkyl, (C1-C4)alkyl-heterocycloalkyl-(C0-C4)alkoxy, (C1-C4)haloalkoxy, halogen, cyano, cyano-(C1-C4)alkyl, cyano-(C1-C4)alkyl-heterocycloalkyl, CONR1R2, NHCOR1, NR1R2, R1R2N—(C1-C4)alkyl, heterocycloalkyl, (C1-C4)alkyl-heterocycloalkyl, heterocycloalkyl-(C1-C4)alkyl, (C1-C4)alkyl-heterocycloalkyl-carbonyl, (C0-C4)alkyl-heterocycloalkyl-carbonyl, (C1-C4)alkyl-phenyl and monocyclic (C1-C4)alkyl-heteroaryl;
- R1 and R2 are independently selected from the group consisting of hydrogen, (C1-C4)alkyl, (C1-C4)hydroxyalkyl, (C1-C4)alkoxy(C1-C4)alkyl, (C1-C4)alkylamino-(C1-C4)alkyl, di-(C1-C4)alkylamino-(C1-C4)alkyl, optionally substituted (C3-C6)cycloalkyl, optionally substituted heterocycloalkyl and optionally substituted heterocycloalkyl-(C1-C4)alkoxy, wherein optional substituents are one or more and are selected from (C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)haloalkyl and (C1-C4)haloalkoxy;
- and
- R3 is selected from the group consisting of hydrogen and (C1-C4)alkyl;
- or a stereoisomer, tautomer, solvate or pharmaceutically acceptable salt thereof.
13 more elements
15:
- A process for preparing the compound, or stereoisomer, tautomer, solvate or pharmaceutically acceptable salt thereof, according to claim 2, comprising reacting an intermediate compound of formula (XXXIII) and/or an intermediate compound of formula (XXXIX) and/or an intermediate compound of formula (XL):
- wherein
- R is (C1-C4)alkyl,
- A is a ring selected from the group consisting of:
- and phenyl, wherein indicates a direct bond to NH;
- W1 and W2 are substituents of ring A selected from the group consisting of hydrogen, halogen, (C1-C4)alkyl, (C1-C4)haloalkyl, (C1-C4)alkoxy, (C1-C4)haloalkoxy, R1R2N—(C1-C4)alkyl and (C3-C6)cycloalkyl;
- Z is selected from the group consisting of (C1-C4)alkyl, (C1-C4)haloalkyl, (C1-C4)alkoxy, (C1-C4)haloalkoxy, (C1-C4)hydroxyalkyl and (C3-C6)cycloalkyl;
- L1 is selected from the group consisting of O, NR3, CHR3, S and SO2, or is absent;
- B is mono- or bi-cyclic heteroaryl ring;
- Y1 and Y2 are substituents of ring B independently selected from the group consisting of hydrogen, (C1-C4)alkyl, (C1-C4)haloalkyl, (C1-C4)alkoxy, (C1-C4)alkoxy-(C1-C4)alkoxy, hydroxy-(C1-C4)alkoxy, hydroxy-(C1-C4)alkyl, (C1-C4)alkyl-heterocycloalkyl-(C0-C4)alkoxy, (C1-C4)haloalkoxy, halogen, cyano, cyano-(C1-C4)alkyl, cyano-(C1-C4)alkyl-heterocycloalkyl, CONR1R2, NHCOR1, NR1R2, R1R2N—(C1-C4)alkyl, heterocycloalkyl, (C1-C4)alkyl-heterocycloalkyl, heterocycloalkyl-(C1-C4)alkyl, (C1-C4)alkyl-heterocycloalkyl-carbonyl, (C0-C4)alkyl-heterocycloalkyl-carbonyl, (C1-C4)alkyl-phenyl and monocyclic (C1-C4)alkyl-heteroaryl;
- R1 and R2 are independently selected from the group consisting of hydrogen, (C1-C4)alkyl, (C1-C4)hydroxyalkyl, (C1-C4)alkoxy(C1-C4)alkyl, (C1-C4)alkylamino-(C1-C4)alkyl, di-(C1-C4)alkylamino-(C1-C4)alkyl, optionally substituted (C3-C6)cycloalkyl, optionally substituted heterocycloalkyl and optionally substituted heterocycloalkyl-(C1-C4)alkoxy, wherein optional substituents are one or more and are selected from (C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)haloalkyl and C1-C4)haloalkoxy;
- and
- R3 is selected from the group consisting of hydrogen and (C1-C4)alkyl.
10 more elements
Dependencies are inferred from the claim text.